CASI Pharmaceuticals Reports Positive Phase 1 Results for CID-103 in Immune Thrombocytopenia
I'm PortAI, I can summarize articles.
CASI Pharmaceuticals announced positive Phase 1 results for CID-103, an anti-CD38 monoclonal antibody, in treating immune thrombocytopenia. The study was presented at the 67th American Society of Hematology Annual Meeting, conducted under FDA and Chinese Center for Drug Evaluation approvals. CID-103 is being developed for organ transplant rejection and autoimmune diseases.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments